SLC51B

Summary

SLC51B (SLC51 subunit beta, HGNC:29956) is a protein-coding gene on chromosome 15q22.31, encoding Organic solute transporter subunit beta (Q86UW2). Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood.

Predicted to enable bile acid transmembrane transporter activity and protein heterodimerization activity. Involved in bile acid secretion. Located in basolateral plasma membrane.

Source: NCBI Gene 123264 — RefSeq curated summary.

At a glance

• Gene–disease (curated): bile acid malabsorption, primary, 2 (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 8 total
• Phenotypes (HPO): 14
• MANE Select transcript: NM_178859

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29956
Approved symbol	SLC51B
Name	SLC51 subunit beta
Location	15q22.31
Locus type	gene with protein product
Status	Approved
Aliases	OSTbeta, SLC51A1BP
Ensembl gene	ENSG00000186198
Ensembl biotype	protein_coding
OMIM	612085
Entrez	123264

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000334287, ENST00000886654, ENST00000886655, ENST00000950357

RefSeq mRNA: 1 — MANE Select: NM_178859 NM_178859

CCDS: CCDS10199

Canonical transcript exons

ENST00000334287 — 4 exons

Exon	Start	End
ENSE00001331282	65051515	65051605
ENSE00001331283	65052966	65053397
ENSE00001331285	65049897	65050101
ENSE00001378826	65045387	65045582

Expression profiles

Bgee: expression breadth ubiquitous, 164 present calls, max score 98.58.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3737 / max 161.6063, expressed in 64 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
147213	0.1426	32
147214	0.0607	20
147209	0.0491	12
147215	0.0296	15
147216	0.0271	10
147211	0.0265	16
147212	0.0191	11
147208	0.0098	5
147210	0.0091	4

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	98.58	gold quality
mucosa of transverse colon	UBERON:0004991	98.22	gold quality
duodenum	UBERON:0002114	93.56	gold quality
rectum	UBERON:0001052	90.90	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.55	gold quality
transverse colon	UBERON:0001157	89.02	gold quality
small intestine	UBERON:0002108	88.55	gold quality
jejunal mucosa	UBERON:0000399	88.14	gold quality
colonic mucosa	UBERON:0000317	87.82	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.37	gold quality
mucosa of sigmoid colon	UBERON:0004993	85.33	gold quality
popliteal artery	UBERON:0002250	84.30	gold quality
tibial artery	UBERON:0007610	84.30	gold quality
kidney epithelium	UBERON:0004819	83.23	silver quality
intestine	UBERON:0000160	83.09	gold quality
aorta	UBERON:0000947	82.60	gold quality
large intestine	UBERON:0000059	81.51	gold quality
colon	UBERON:0001155	81.29	gold quality
right coronary artery	UBERON:0001625	80.68	gold quality
descending thoracic aorta	UBERON:0002345	80.66	gold quality
thoracic aorta	UBERON:0001515	80.65	gold quality
ascending aorta	UBERON:0001496	80.63	gold quality
adult mammalian kidney	UBERON:0000082	79.49	gold quality
left uterine tube	UBERON:0001303	78.82	gold quality
smooth muscle tissue	UBERON:0001135	78.28	gold quality
mucosa of stomach	UBERON:0001199	78.10	gold quality
left coronary artery	UBERON:0001626	78.02	gold quality
left testis	UBERON:0004533	77.56	gold quality
right testis	UBERON:0004534	77.26	gold quality
coronary artery	UBERON:0001621	76.98	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	68.33
E-ANND-3	yes	6.78

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR0B2, NR1H3, NR1H4, NR1I3, NR5A2, RARA

miRNA regulators (miRDB)

9 targeting SLC51B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4639-5P	99.81	67.37	1028
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-4686	98.77	66.87	964
HSA-MIR-10226	98.25	66.50	811
HSA-MIR-1972	97.67	67.38	1172
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-4327	97.21	67.71	676
HSA-MIR-1231	95.10	65.63	663

Literature-anchored findings (GeneRIF, showing 16)

• OSTbeta has roles in biological transport and is widely expressed in human tissues (PMID:12719432)
• overexpression of human OSTalpha and OSTbeta facilitated the uptake of conjugated chenodeoxycholate and the activation of FXR target genes (PMID:16251721)
• OSTalpha/OSTbeta expression is induced by bile acids through ligand-dependent transactivation of both OST genes by the nuclear bile acid receptor/farnesoid X receptor (FXR). (PMID:16269519)
• the selective localization of OSTalpha and OSTbeta to the basolateral plasma membrane of epithelial cells responsible for bile acid and sterol reabsorption. (PMID:16317684)
• These results indicate that expression of Ostalpha and Ostbeta are highly regulated in response to cholestasis and that this response is dependent on the FXR bile acid receptor. (PMID:16423920)
• Demonstrate association of OST-alpha and OST-beta to determine trafficking to plasma membrane and activity. (PMID:17332473)
• The mRNA expression of OSTalpha-OSTbeta was significantly reduced (OSTalpha: 3.3-fold, P = 0.006; OSTbeta: 2.6-fold, P = 0.03) in normal-weight but not overweight gallstone carriers (PMID:18469300)
• interaction of solute transporter beta with human organic solute transporter alpha. (PMID:18847488)
• OSTbeta is localized to steroidogenic cells of the brain and adrenal gland, and it modulates DHEA/DHEAS homeostasis (PMID:20649839)
• The present report summarizes the evidence for a pleiotropic role of Ostalpha-Ostbeta in different tissues. (PMID:21691099)
• Ostbeta is required for both proper trafficking of Ostalpha and formation of the functional transport unit, and identify specific residues of Ostbeta critical for these processes. (PMID:22535958)
• OSTbeta is a target of RARalpha-mediated (by binding to DR5 response element) gene regulation pathways (PMID:24264050)
• Hepatic OSTalpha-OSTbeta expression is induced by hypoxia. (PMID:24703425)
• Dileucine motif in the extracellular N-terminal region is essential for OSTB plasma membrane targeting. (PMID:27351185)
• Study found lower organic solute transporter beta (OSTbeta) expression in colon cancer tissues compared with adjacent normal tissues and revealed the epigenetic mechanisms of it and proved that p300 controls OSTbeta expression through modulating H3K27Ac state at OSTbeta promoter region and hence causes low expression of OSTbeta in colorectal cancer. (PMID:32005758)
• HNF1A binds and regulates the expression of SLC51B to facilitate the uptake of estrone sulfate in human renal proximal tubule epithelial cells. (PMID:37137894)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Slc51b	ENSMUSG00000053862
rattus_norvegicus	Slc51b	ENSRNOG00000028889

Protein

Protein identifiers

Organic solute transporter subunit beta — Q86UW2 (reviewed: Q86UW2)

Alternative names: Solute carrier family 51 subunit beta

All UniProt accessions (1): Q86UW2

UniProt curated annotations — full annotation on UniProt →

Function. Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Modulates SLC51A glycosylation, membrane trafficking and stability activities. The Ost-alpha/Ost-beta complex efficiently transports the major species of bile acids (taurocholate). Taurine conjugates are transported more efficiently across the basolateral membrane than glycine-conjugated bile acids. Can also transport steroids such as estrone 3-sulfate and dehydroepiandrosterone 3-sulfate, therefore playing a role in the enterohepatic circulation of sterols. Able to transport eicosanoids such as prostaglandin E2.

Subunit / interactions. Interacts with SLC51A. The Ost-alpha/Ost-beta complex is a heterodimer composed of alpha (SLC51A) and beta (SLC51B) subunit; induces the transport of SLC51A from the endoplasmic reticulum to the plasma membrane.

Subcellular location. Cell membrane.

Tissue specificity. Widely expressed with a high expression in ileum. Expressed in testis, colon, liver, small intestine, kidney, ovary and adrenal gland; and at low levels in heart, lung, brain, pituitary, thyroid gland, uterus, prostate, mammary gland and fat.

Disease relevance. Bile acid malabsorption, primary, 2 (PBAM2) [MIM:619481] An autosomal recessive disorder characterized by chronic diarrhea, severe fat-soluble vitamin deficiency, and features of cholestatic liver disease. The disease may be caused by variants affecting the gene represented in this entry.

Domain organisation. The transmembrane domain (TM) is the major site of interaction with SLC51A. The extracellular-membrane interface is absolutely required for transport activity. The intracellular-membrane interface is necessary for establishing the correct membrane orientation that is essential for the heterodimer Ost-alpha/Ost-beta complex formation and transport activity at the cell membrane surface.

Induction. Positively regulated via NR1H4/FXR.

Similarity. Belongs to the OST-beta family.

RefSeq proteins (1): NP_849190* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029387	OSTbeta	Family
IPR052678	OST-beta_subunit	Family

Pfam: PF15048

Catalyzed reactions (Rhea), 11 shown:

• prostaglandin E2(out) = prostaglandin E2(in) (RHEA:50984)
• taurocholate(out) = taurocholate(in) (RHEA:71703)
• estrone 3-sulfate(out) = estrone 3-sulfate(in) (RHEA:71835)
• dehydroepiandrosterone 3-sulfate(out) = dehydroepiandrosterone 3-sulfate(in) (RHEA:71839)
• tauroursodeoxycholate(out) = tauroursodeoxycholate(in) (RHEA:71843)
• glycoursodeoxycholate(out) = glycoursodeoxycholate(in) (RHEA:71847)
• glycocholate(out) = glycocholate(in) (RHEA:71851)
• taurochenodeoxycholate(out) = taurochenodeoxycholate(in) (RHEA:71855)
• glycochenodeoxycholate(out) = glycochenodeoxycholate(in) (RHEA:71859)
• taurodeoxycholate(out) = taurodeoxycholate(in) (RHEA:71863)
• glycodeoxycholate(out) = glycodeoxycholate(in) (RHEA:71867)

UniProt features (5 total): topological domain 2, chain 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
9UO2	ELECTRON MICROSCOPY	2.6
9LJG	ELECTRON MICROSCOPY	2.64
9LJH	ELECTRON MICROSCOPY	2.73
9UO1	ELECTRON MICROSCOPY	2.9
9UNV	ELECTRON MICROSCOPY	3.12

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UW2-F1	67.47	0.12

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-159418	Recycling of bile acids and salts

MSigDB gene sets: 123 (showing top): GOBP_ACID_SECRETION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_PROTEIN_TARGETING, GOBP_REGULATION_OF_PROTEIN_TARGETING_TO_MEMBRANE, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_TRANSPORT, GOBP_REGULATION_OF_GLYCOPROTEIN_METABOLIC_PROCESS, GOBP_PROTEIN_TARGETING_TO_MEMBRANE, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE

GO Biological Process (9): positive regulation of glycoprotein biosynthetic process (GO:0010560), bile acid and bile salt transport (GO:0015721), regulation of protein stability (GO:0031647), bile acid secretion (GO:0032782), positive regulation of protein exit from endoplasmic reticulum (GO:0070863), positive regulation of protein targeting to membrane (GO:0090314), lipid transport (GO:0006869), transmembrane transport (GO:0055085), obsolete positive regulation of protein glycosylation (GO:0060050)

GO Molecular Function (4): bile acid transmembrane transporter activity (GO:0015125), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515), transmembrane transporter activity (GO:0022857)

GO Cellular Component (4): plasma membrane (GO:0005886), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Bile acid and bile salt metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
monocarboxylic acid transport	2
transport	2
glycoprotein biosynthetic process	1
positive regulation of macromolecule biosynthetic process	1
regulation of glycoprotein biosynthetic process	1
positive regulation of glycoprotein metabolic process	1
lipid transport	1
organic hydroxy compound transport	1
regulation of biological quality	1
acid secretion	1
protein exit from endoplasmic reticulum	1
regulation of protein exit from endoplasmic reticulum	1
positive regulation of intracellular protein transport	1
protein targeting to membrane	1
positive regulation of cellular process	1
regulation of protein targeting to membrane	1
positive regulation of establishment of protein localization	1
lipid localization	1
cellular process	1
bile acid and bile salt transport	1
carboxylic acid transmembrane transporter activity	1
lipid transmembrane transporter activity	1
protein dimerization activity	1
binding	1
transporter activity	1
transmembrane transport	1
membrane	1
cell periphery	1
cellular anatomical structure	1
basal plasma membrane	1
plasma membrane region	1
cellular_component	1

Protein interactions and networks

STRING

684 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC51B	SLC51A	Q86UW1	999
SLC51B	SLC10A2	Q12908	818
SLC51B	CYP7A1	P22680	813
SLC51B	ABCC3	O15438	808
SLC51B	ABCB11	O95342	787
SLC51B	FABP6	P51161	773
SLC51B	NR1H4	Q96RI1	771
SLC51B	SLC10A1	Q14973	766
SLC51B	CYP8B1	Q9UNU6	718
SLC51B	NR0B2	Q15466	716
SLC51B	FGF19	O95750	675
SLC51B	ABCC2	Q92887	595
SLC51B	SLCO1A2	P46721	594
SLC51B	CYP27A1	Q02318	589
SLC51B	ABCG5	Q9H222	585

IntAct

22 interactions, top by confidence:

A	B	Type	Score
LAT	SLC51B	psi-mi:“MI:0915”(physical association)	0.560
ASPH	SLC51B	psi-mi:“MI:0915”(physical association)	0.560
SLC51B	ETNK1	psi-mi:“MI:0915”(physical association)	0.560
SLC51B	CYB5R1	psi-mi:“MI:0915”(physical association)	0.560
	SLC51B	psi-mi:“MI:0915”(physical association)	0.490
SLC51B	ODR4	psi-mi:“MI:0914”(association)	0.350
SLC51A	TNPO2	psi-mi:“MI:0914”(association)	0.350
SLC51B	CTNND1	psi-mi:“MI:0914”(association)	0.350
LAT	SLC51B	psi-mi:“MI:0915”(physical association)	0.000
ASPH	SLC51B	psi-mi:“MI:0915”(physical association)	0.000
ETNK1	SLC51B	psi-mi:“MI:0915”(physical association)	0.000
CYB5R1	SLC51B	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (27): SLC51B (Two-hybrid), SLC51B (Two-hybrid), ASPH (Two-hybrid), LAT (Two-hybrid), C1orf27 (Affinity Capture-MS), TMEM38B (Affinity Capture-MS), PRR15 (Affinity Capture-MS), RMND1 (Affinity Capture-MS), TMTC4 (Affinity Capture-MS), UFSP2 (Affinity Capture-MS), TMEM205 (Affinity Capture-MS), SLC51B (Two-hybrid), SLC51B (Cross-Linking-MS (XL-MS)), SLC51B (Affinity Capture-MS), ALDH18A1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GU29, A6NLX4, A6QNY1, A9CBA0, B7ZWI3, O14669, O88472, P14784, P16297, P25918, P26896, Q0VFL4, Q13651, Q32M26, Q38J84, Q38J85, Q3SYS8, Q58CT8, Q5BK39, Q5EAA5, Q5HZE8, Q5NCP0, Q5RCL0, Q64322, Q68DV7, Q6AXS2, Q6AXU5, Q6NUJ2, Q6UWV7, Q86UW2, Q8BHB3, Q8BLR5, Q8BSU2, Q8C353, Q8C708, Q8K1T1, Q8MII8, Q8N6P7, Q8NET5, Q8R182

Diamond homologs: A0JNM1, Q80WK2, Q86UW2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

8 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	5
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

465 predictions. Top by Δscore:

Variant	Effect	Δscore
15:65045581:GG:G	donor_gain	1.0000
15:65045582:GG:G	donor_gain	1.0000
15:65051237:G:GG	donor_gain	1.0000
15:65051513:A:AG	acceptor_gain	1.0000
15:65051514:G:GA	acceptor_gain	1.0000
15:65051514:GC:G	acceptor_gain	1.0000
15:65051514:GCAT:G	acceptor_gain	1.0000
15:65051602:GCAG:G	donor_gain	1.0000
15:65051603:CAGG:C	donor_loss	1.0000
15:65051605:GGTG:G	donor_loss	1.0000
15:65051606:G:GA	donor_loss	1.0000
15:65051607:T:A	donor_loss	1.0000
15:65052964:A:AG	acceptor_gain	1.0000
15:65052964:AGAA:A	acceptor_loss	1.0000
15:65052965:G:GA	acceptor_gain	1.0000
15:65052965:GA:G	acceptor_gain	1.0000
15:65052965:GAAAA:G	acceptor_gain	1.0000
15:65045579:CGGGG:C	donor_loss	0.9900
15:65045580:GGG:G	donor_gain	0.9900
15:65045581:GGG:G	donor_gain	0.9900
15:65045581:GGGTG:G	donor_loss	0.9900
15:65045582:GGTG:G	donor_loss	0.9900
15:65045583:G:GG	donor_gain	0.9900
15:65045583:GTGA:G	donor_loss	0.9900
15:65045584:T:A	donor_loss	0.9900
15:65049892:TCCA:T	acceptor_loss	0.9900
15:65049893:CCA:C	acceptor_loss	0.9900
15:65049894:CA:C	acceptor_loss	0.9900
15:65049895:A:AG	acceptor_gain	0.9900
15:65049895:A:T	acceptor_loss	0.9900

AlphaMissense

838 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:65051568:A:C	S51R	0.982
15:65051570:C:A	S51R	0.982
15:65051570:C:G	S51R	0.982
15:65051525:G:C	W36C	0.973
15:65051525:G:T	W36C	0.973
15:65051523:T:A	W36R	0.966
15:65051523:T:C	W36R	0.966
15:65050086:T:C	F28L	0.941
15:65050088:T:A	F28L	0.941
15:65050088:T:G	F28L	0.941
15:65050082:G:C	W26C	0.916
15:65050082:G:T	W26C	0.916
15:65050080:T:A	W26R	0.901
15:65050080:T:C	W26R	0.901
15:65051566:T:A	I50K	0.896
15:65050089:C:A	R29S	0.895
15:65050090:G:C	R29P	0.892
15:65051557:T:A	V47E	0.875
15:65051545:T:G	L43R	0.874
15:65051551:C:A	A45D	0.874
15:65051560:T:A	V48D	0.872
15:65051542:C:A	A42D	0.869
15:65051545:T:C	L43P	0.863
15:65051545:T:A	L43Q	0.844
15:65050087:T:G	F28C	0.841
15:65051524:G:C	W36S	0.840
15:65050087:T:C	F28S	0.837
15:65052966:A:C	R63S	0.835
15:65052966:A:T	R63S	0.835
15:65051566:T:G	I50R	0.825

dbSNP variants (sampled 300 via entrez): RS1000120204 (15:65052333 T>G), RS1000456371 (15:65052288 C>T), RS1000552319 (15:65051904 C>T), RS1000781291 (15:65047514 G>A), RS1001440137 (15:65053633 G>A), RS1001620875 (15:65044267 A>G), RS1001863745 (15:65048958 A>C), RS1001917549 (15:65048768 G>A), RS1001932218 (15:65046262 C>T), RS1002047150 (15:65044737 AAAAAAAAAAAAAAAAAAAAAAG>A), RS1002173236 (15:65050499 G>C), RS1002420150 (15:65052764 A>G), RS1002919236 (15:65050134 G>A), RS1003218381 (15:65043573 C>T), RS1003477017 (15:65047688 A>C)

Disease associations

OMIM: gene MIM:612085 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
bile acid malabsorption, primary, 2	Limited	Unknown

Mondo (1): bile acid malabsorption, primary, 2 (MONDO:0859180)

Orphanet (0):

HPO phenotypes

14 total (14 of 14 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0001405	Periportal fibrosis
HP:0002028	Chronic diarrhea
HP:0002570	Steatorrhea
HP:0003623	Neonatal onset
HP:0004905	Reduced circulating vitamin A concentration
HP:0006579	Prolonged neonatal jaundice
HP:0025321	Copper accumulation in liver
HP:0030948	Elevated gamma-glutamyltransferase level
HP:0031956	Elevated circulating aspartate aminotransferase concentration
HP:0031964	Elevated circulating alanine aminotransferase concentration
HP:0034048	Decreased circulating chenodeoxycholic acid concentration
HP:0100512	Decreased circulating vitamin D concentration
HP:0100513	Decreased circulating vitamin E concentration

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010101_13	White matter hyperintensities	6.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005665	white matter hyperintensity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC51 family of steroid-derived molecule transporters

CTD chemical–gene interactions

79 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Chenodeoxycholic Acid	affects cotreatment, increases expression, decreases expression, decreases reaction, affects reaction	9
Cyclosporine	affects cotreatment, affects expression, increases expression, decreases expression	8
Deoxycholic Acid	affects cotreatment, increases expression	4
perfluorooctane sulfonic acid	increases expression, affects binding, increases transport	3
Benzo(a)pyrene	affects methylation, decreases expression, increases expression, increases methylation	3
Glycochenodeoxycholic Acid	increases uptake, affects cotreatment, increases expression, affects binding, decreases reaction	3
Glycocholic Acid	affects cotreatment, increases expression, affects binding, decreases reaction, increases uptake	3
Triclosan	affects cotreatment, increases expression, decreases expression	3
sodium arsenite	decreases expression, increases expression	2
Cisplatin	affects cotreatment, increases expression	2
Glycodeoxycholic Acid	affects cotreatment, increases expression	2
Lithocholic Acid	increases expression	2
Phenobarbital	increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Aflatoxin B1	increases expression	2
fluorotelomer sulfonic acids	increases expression	1
6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt	affects cotreatment, increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
perfluorooctanoic acid	increases expression	1
tri-o-cresyl phosphate	increases expression	1
resorcinol	decreases expression	1
epigallocatechin gallate	decreases reaction, increases expression	1
nefazodone	affects cotreatment, increases expression	1
perfluorooctanesulfonamide	decreases expression	1
NCS 382	increases expression	1
fipronil	affects cotreatment, increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4U1	HuH7-SLC51B-KO-c10	Cancer cell line	Male
CVCL_D4U2	HuH7-SLC51B-KO-c2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.